Skip to main content
. 2019 Aug 2;31(1):e8. doi: 10.3802/jgo.2020.31.e8

Table 3. Stratified analysis for associations between surgery of primary sites and OS of stage IVB cervical cancer patients receiving CRT (matched).

Select covariates Treatment
Total/death HR 95% CI p
Age at diagnosis
≤50 132/68 0.32 0.15–0.68 0.003
>50 84/42 0.17 0.06–0.50 0.001
Race
White 170/81 0.34 0.18–0.65 <0.001
Black 27/18 <0.01 4.01–448,500 0.015
Other* 19/3 - - 0.999
Marital status
No 94/42 0.50 0.15–1.61 0.243
Yes 107/57 0.20 0.08–0.47 <0.001
Insurance record
No 21/12 - - 0.998
Yes 192/96 0.36 0.20–0.63 <0.001
Grade
I–II 92/44 0.12 0.03–0.41 <0.001
III–IV 97/55 0.47 0.22–1.02 0.056
Histology
SCC 123/57 0.67 0.30–1.55 0.366
Adenocarcinoma 50/28 0.18 0.04–0.88 0.034
Other 43/25 <0.01 0.00–0.02 <0.001
Tumor size (cm)
≤4 152/72 0.22 0.11–0.46 <0.001
>4 41/20 0.89 0.18–4.41 0.888
AJCC T stage
T1 78/30 - - 0.997
T2 68/35 0.60 0.24–1.52 0.286
T3 60/39 0.26 0.09–0.81 0.021
T4 10/6 - - -
AJCC N stage
N0 54/26 0.43 0.09–2.22 0.327
N1 156/80 0.30 0.16–0.56 <0.001
Visceral metastasis
No 122/53 0.31 0.14–0.70 0.005
Yes
Distant organ only 52/30 1.38 0.28–6.70 0.590
Distant LN plus organ 35/22 0.03 0.00–0.34 0.005

The results were adjusted for age at diagnosis, race, marital status, insurance record, grade, histology, AJCC T stage, AJCC N stage, visceral metastasis, and the significant results in bold, if p<0.05.

AJCC, American Joint Committee on Cancer; CI, confidence interval; CRT, chemoradiotherapy; HR, hazards ratio; LN, lymph node; NOS, not otherwise specified; OS, overall survival; SCC, squamous cell carcinoma.

*Race–others (Asian or Pacific Islander; American Indian/Alaska Native); Histology–others (epithelial neoplasms, NOS; transitional cell papillomas and carcinomas; cystic, mucinous and serous neoplasms; complex epithelial neoplasms; complex mixed and stromal neoplasms; unspecified neoplasms).